Publicaciones en colaboración con investigadores/as de Hospital del Mar (6)

2023

  1. Liquid Biopsy Detects Early Molecular Response and Predicts Benefit to First-Line Chemotherapy plus Cetuximab in Metastatic Colorectal Cancer: PLATFORM-B Study

    Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 29, Núm. 2, pp. 379-388

  2. Total neoadjuvant therapy with or without aflibercept in rectal cancer: 3-year results of GEMCAD-1402

    Journal of the National Cancer Institute, Vol. 115, Núm. 12, pp. 1497-1505

2021

  1. Clinical impact of presurgery circulating tumor DNA after total neoadjuvant treatment in locally advanced rectal cancer: A biomarker study from the GEMCAD 1402 trial

    Clinical Cancer Research, Vol. 27, Núm. 10, pp. 2890-2898

2019

  1. Effect of Aflibercept Plus Modified FOLFOX6 Induction Chemotherapy before Standard Chemoradiotherapy and Surgery in Patients with High-Risk Rectal Adenocarcinoma: The GEMCAD 1402 Randomized Clinical Trial

    JAMA Oncology, Vol. 5, Núm. 11, pp. 1566-1573

  2. Ultra-selection of metastatic colorectal cancer patients using next-generation sequencing to improve clinical efficacy of anti-EGFR therapy

    Annals of Oncology, Vol. 30, Núm. 3, pp. 439-446

2014

  1. Figitumumab in patients with refractory metastatic colorectal cancer previously treated with standard therapies: A nonrandomized, open-label, phase II trial

    Cancer Chemotherapy and Pharmacology, Vol. 73, Núm. 4, pp. 695-702